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Abstract Genome wide association studies (GWAS) for
Parkinson’s disease (PD) have previously revealed a signif-
icant association with a locus on chromosome 7p15.3, ini-
tially designated as the glycoprotein non-metastatic melano-
ma protein B (GPNMB) locus. In this study, the functional
consequences of this association on expression were ex-
plored in depth by integrating different expression quanti-
tative trait locus (eQTL) datasets (Braineac, CAGEseq,
GTEx, and Phenotype-Genotype Integrator (PheGenI)).
Top risk SNP rs199347 eQTLs demonstrated increased ex-
pressions of GPNMB, KLHL7, and NUPL2 with the major
allele (AA) in brain, with most significant eQTLs in corti-
cal regions, followed by putamen. In addition, decreased
expression of the antisense RNA KLHL7-AS1 was observed
in GTEx. Furthermore, rs199347 is an eQTL with long
non-coding RNA (AC005082.12) in human tissues other
than brain. Interestingly, transcript-specific eQTLs in
immune-related tissues (spleen and lymphoblastoid cells)
for NUPL2 and KLHL7-AS1 were observed, which sug-
gests a complex functional role of this eQTL in specific
tissues, cell types at specific time points. Significantly in-
creased expression of GPNMB linked to rs199347 was con-
sistent across all datasets, and taken in combination with
the risk SNP being located within the GPNMB gene, these
results suggest that increased expression of GPNMB is the
causative link explaining the association of this locus with
PD. However, other transcript eQTLs and subsequent func-
tional roles cannot be excluded. This highlights the impor-
tance of further investigations to understand the functional
interactions between the coding genes, antisense, and non-
coding RNA species considering the tissue and cell-type
specificity to understand the underlying biological mecha-
nisms in PD.
Keywords Chr7 locus (GPNMB) . Antisense and non-coding
RNA . Human brain expressionQTLs . Parkinson’s disease
(PD) . Risk SNP rs199347
Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disease, characterized by movement-related
symptoms including bradykinesia, rigidity, and tremor, as well
as an increasingly appreciated array of non-movement issues
[1]. The symptoms derive from extensive neuronal cell death,
most notably (but not exclusively) of dopaminergic neurons
within the substantia nigra pars compacta. The etiology of
PD is complex, and is thought to involve the interplay of
several factors, including environmental exposure and genetic
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predisposition. Our understanding of the latter has undergone
a transformation in the last two decades, moving from fully
penetrant causative variants inherited in a Mendelian fashion
to subtle risk factors impacting on transcript expression, gene-
gene interactions, gene-protein interactions, and other down-
stream processes in different tissues and specific cell type [2].
In recent years, genome wide association (GWA) meta-
analyses have opened a new window on how common varia-
tion in the general population can increase lifetime risk of
developing PD. The most recent of these, a meta-analysis
study conducted by Nalls et al. included 13,708 cases and
95,282 controls, identified 26 risk loci of which 6 were novel.
Thirty significant associations between SNPs of interest and
either CpG methylation or messenger RNA (mRNA) expres-
sion profiles across the six newly identified loci were identi-
fied [3]. Thus, the application of GWA approaches over the
past decade have identified a large number of loci associated
with increased risk of PD and helped prioritize genomic re-
gions of interest for further functional characterization.
A major challenge for the Parkinson’s community is, there-
fore, to decipher the functional sequelae of the variants iden-
tified by GWA studies in order to achieve a deeper under-
standing of the genetic etiology of PD and uncover novel drug
targets/pathways, thereby accelerating drug development.
Parallel studies by a number of groups using different exper-
imental approaches have investigated the functional roles of
these variants such as their effects on gene expression (expres-
sion quantitative trait loci (eQTLs)) [4–7], long non-coding
RNA trans-regulation [8], and protein-protein interaction net-
works [9] providing substantial insights into disease mecha-
nisms for a number of common disorders. The impact of
eQTLs is of particular interest as it can provide compelling
evidence linking a risk variant and disease-specific genetic
alterations in terms of altered expression and splicing levels,
therefore yielding insight into the disease association and
mechanism. Hence, an eQTL analytical approach can bridge
the gap between the structural variants and their functional
and regulatory implications which can facilitate further inte-
grative analyses.
A number of eQTL studies have been conducted for differ-
ent human diseases in order to understand the effect of the
associated variants on the candidate transcripts. For example,
prostate cancer risk SNPs were analyzed from 471 prostate
tissues [10], identifying 51 significant eQTLs associated with
88 genes. In a subsequent study, an eQTL mapping approach
was applied to human inflammatory bowel (IBD) diseases in
five primary immune cell types. This study involved 91 pa-
tients with active inflammatory disease, 46 with antineutrophil
cytoplasmic antibody-associated vasculitis, and 43 healthy
controls. As a result, novel eQTLs in 34 IBD-associated loci
were reported [11]. Other eQTL studies were performed at a
genome wide scale in different control human tissues such as
liver [12], blood and brain [13], and monocytes [14].
Outcomes of these studies highlighted the importance of
tissue-specific eQTL and splicing QTLs in human disease.
In the context of brain disorders, a number of datasets are
now publically available to look at gene expression on a re-
gional and temporal basis [15, 16]. eQTL results from the
Braineac dataset, which integrates whole genome genotype
and transcript expression data from 134 human control brain
samples of 10 brain regions [7, 17], allowing examination of
genes implicated in PD by GWA analyses. Studies focusing
on specific three PD loci, alpha synuclein (SNCA) [18],
microtubule-associated protein tau (MAPT) [19], and
leucine-rich repeat kinase (LRRK2) [4], were investigated sep-
arately in detail and have been published previously. In addi-
tion, targeted eQTL approaches have been applied in the con-
text of PD by Latourelle and coworkers. The transcript expres-
sion profiling was performed on 23 PD prefrontal cortex brain
cases and 24 controls in 5 GWAS-identified loci (SNCA,
MAPT, GAK/DGKQ, HLA, and RIT2). The study identified
multiple eQTLs which include both cis-acting SNP effects
as well as trans-effects [20].
In this current study, the hypothesis that PD GWA risk
SNP r s 199347 t a gg i n g t h e g enom i c l o c a t i o n
Chr7:23,145,089-23,314,256 bp (GRCh37) (Fig. 1) segre-
gates as an eQTL with some or all of the transcripts at this
genomic region. This hypothesis was tested by exploring all
eQTLs of these five transcripts at this locus (GPNMB,
KLHL7, KLHL7-AS1, NUPL2, and AC005082.12) using the
Braineac microarray dataset [17]; a recent CAGEseq dataset
[21]; GTEx Portal, which uses RNA sequence platform [22];
and NCBI’s Phenotype-Genotype Integrator (PheGenI) [6].
The performed analysis here does not cover epigenetic effect;
however, it is a comprehensive analysis of reported GWAS
signal (rs199347) in different brain tissues as well as other
human tissues using multiple datasets including our in-house
dataset (Braineac) and as a result, a step forward from Nalls
et al. study [3].
Results
In this study, we examined the functional effect of the PD risk
SNP rs199347 on the mRNA expression levels of the tran-
scripts at the Chr7p15.3 locus. This was performed by inte-
grating expression data from different human brain tissues
from Braineac, alongside other human tissues accessed via
the GTEx portal through an eQTL approach (refer to Table 1
and Supplementary Table 1 for further details on the human
tissues in GTEx) and an eQTL data generated from human
frontal lobe tissues based on cap analysis gene expression
sequencing (CAGEseq).
Firstly, expression profiling for the five transcripts in the
locus under consideration (GPNMB, KLHL7, KLHL7-AS1,
NUPL2, and AC005082.12) (Fig. 1) were compared using
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Braineac and GTEx datasets (refer to Fig. 2 for the locus
details). The expression profiles for the antisense KLHL7-
AS1and long non-coding RNA (AC005082.12) species were
attained from GTEx only as the microarray platform design
does not cover long non-coding RNA species. The expression
pattern of glycoprotein non-metastatic melanoma protein B
(GPNMB) from the Braineac dataset revealed significant re-
gional expression differences (2.4-fold change (FC),
p = 4.5 × 10−43; refer to the BMaterials and methods^ section
for further details) with TCTX showing the highest expression
and cerebellum (CRBL) showing the lowest expression
(Fig. 3a). The same pattern was confirmed from GTEx data
showing lowest expression in CRBL and highest in cortical
regions. Due to differences between the precise regions
assessed in the different datasets, comparisons were per-
formed among the most relevant matching brain region be-
tween the Braineac and GTEx datasets (Table 2). The expres-
sion level difference in the Kelch-like protein 7 (KLHL7) tran-
script observed in the Braineac dataset was a 1.5 FC with
CRBL exhibiting the highest expression and white matter
(WHMT) showing the lowest expression (p = 1.2 × 10−31;
Fig. 3b), with similar pattern observed in the GTEx dataset
showing a high expression in the cerebellar hemisphere in
comparison with other brain regions. For nucleoporin-like
protein 2 (NUPL2) transcript, a 1.2 FC with substantia nigra
(SNIG) being the lowest and TCTX being the highest
(p = 8.7 × 10−13) were observed (Fig. 3c) in Braineac.
However, this was not the case in GTEx as CRBL showed
the highest expression level followed by cortical regions. This
can be understandable and we must allow expression variabil-
ity, as it can be raised based on different platforms, dissection
and extraction protocols, and quality controls between the two
datasets.
Secondly, the eQTL analyses for the PD risk SNP rs199347
in relation with the five transcripts were studied in detail using
the abovementioned datasets. The investigation of rs199347,
which is located in introns 2–3 of the GPNMB gene, showed
significant eQTLs in several brain regions in all the four eQTL
datasets, which are Braineac, CAGEseq, GTEx, and PheGenI.
In Braineac, rs199347 was recorded as a significant eQTL
with the GPNMB transcript (p = 8 × 10−13, average across
all regions). The SNP is associated with increased mRNA
expression with the major allele AA in temporal cortex
(TCTX), frontal cortex (FCTX), hippocampus (HIPP), puta-
men (PUTM), occipital cortex (OCTX), and CRBL in normal
individuals (Fig. 4a and Table 1). In the CAGEseq dataset,
rs199347 was a significant eQTL in FCTX (p = 1.6 × 10−11)
also for the major allele AA (Table 3 and Supplementary
Table 3). In GTEx, rs199347 was also a significant eQTL in
the brain (FCTX, caudate, HIPP, PUTM, and CRBL) and in
heart and skin showing the samemode of effect (MOE) on the
expression (+). In Table 1, further details and summary about
eQTLs, mode of effect, and false discovery rate (FDR) values
for GPNMB in the four eQTL datasets are shown. It is worth
mentioning that several other eQTLs were found to be signif-
icant in GPNMB. For example, rs156425, rs6967526, and
rs858272 were found to be significant in several brain regions
across all datasets studied. The rs156425 was observed with
the highest significance in FCTX, TCTX, OCTX, and PUTM,
while rs6967526 and rs858272 showed high significance in
FCTX, TCTX, OCTX, PUTM, and HIPP. The fact that the
above SNPs belong to the same linkage disequilibrium (LD)
as rs199347 justify their significance as eQTLs in the similar
brain regions (refer to Table 1 for further details).
Thirdly, deeper analysis revealed that rs199347 SNP is
associated not only with increased expression of the
GPNMB transcript in brain but also with altered expression
of four other transcripts at this locus, which are KLHL7,
KLHL7-AS1, NUPL2, and AC005082.12 (Tables 3 and 4
and Supplementary Table2). In GTEx, these transcripts dem-
onstrated significant eQTL association resulting in decreased
expression of KLHL7 mRNA in thyroid and brain (nucleus
accumbens) and increased expression in heart and skeletal
muscle with FDR values ranging from 2.4 × 10−06 to
3.7 × 10−10 (Table 3 and Supplementary Table 2); although
the similar expression effect was observed in Braineac, this
eQTL did not pass the multiple correction FDR threshold
(Fig. 4b). Most importantly, rs199347 shows the highest sig-
nificant eQTL associations with KLHL7-AS1 (antisense
RNA1) and has decrease effect on the expression in 41 tissues
(FDR ranging from 1 × 10−13 to 1 × 10−39) such as heart, lung,
Fig. 1 Regional association plot for rs199347 SNP at Chr7p15.3 locus
from discovery phase. The plot shows regions ±1 Mb most significant
SNP from PD GWAS study and the five transcripts in the locus
investigated in this study. This locus was named as GPNMB locus.
Only the five transcripts at this locus are shown in this figure.
Figure modified from Nalls et al. [3]
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and many others. including brain regions (anterior cingulate
cortex, HIPP, caudate, CRBL, FCTX, PUTM, and cortex)
with less significant association (FDR ranging from
1 × 10−06 to 1 × 10−13) and increase effect on the expression
in immune system tissue (spleen; FDR 3 × 10−10) (refer to
Table 4 and Supplementary Table 2). In addition, rs199347
is associated with expression of a long non-coding RNA
(AC005082.12) in tissues other than brain. This long non-
coding RNA is located 29 kb 5′ to the GPNMB transcript
(Fig. 2, Table 4, and Supplementary Table 2). It is important
to mention that the expression profile and eQTL analyses for
KLHL7-AS1 and long non-coding RNA (AC005082.12) could
Table 1 rs199347 is a GPNMB
eQTL specifically in the human
brain tissues in Braineac, GTEx,
CAGEseq, and PheGenI
GPNMB Tissue specificity (brain) No. of
tissue
SNP
(MOE)
p value FDR
Braineac Average across all 10 regions (aveALL) 134 rs199347
(+)
8.00E−13 5.10E−10
Cerebellum (CRBL) 2.60E−06 7.57E−03
Frontal cortex (FCTX) (BA 9,46) 3.70E−11 2.55E−08
Hippocampus (HIPP) 5.20E−07 8.94E−05
Medulla inferior olivary nucleus
(MEDU)
2.00E−01 7.29E−01
Occipital cortex (OCTX) 3.30E−09 2.34E−06
Putamen (PUTM) 3.50E−08 3.22E−05
Substantia nigra (SNIG) 4.90E−01 8.81E−01
Temporal cortex (TCTX) 4.10E−11 1.60E−08
Thalamus (THAL) 2.50E−03 2.72E−01
Intralobular white matter (WHMT) 1.40E−02 4.51E−01
Total 10 tissues
GTEx Brain—anterior cingulate cortex
(BA24)
72 rs199347 (+) 4.60E−10
Brain—caudate (basal ganglia) 100 5.80E−13
Brain—cerebellar hemisphere 89 2.50E−10
Brain—cerebellum 103 3.20E−07
Brain—cortex 96 1.70E−15
Brain—frontal cortex (BA9) 92 1.30E−12
Brain—hippocampus 81 1.10E−07
Brain—hypothalamus 81 2.80E−09
Brain—nucleus accumbens (basal
ganglia)
93 2.10E−09
Brain—putamen (basal ganglia) 82 2.00E−12
Heart—atrial appendage 159 3.20E−13
Heart—left ventricle 190 2.10E−17
Prostate 87 1.20E−06
Skin—sun exposed (lower leg) 302 7.70E−09
Total 14 tissues 1627
PheGenI Brain frontal cortex 143 rs199347
(+)
NA 7.58E−17
CAGEseq Brain frontal cortex 119 rs199347
(+)
1.60E−11 4.97E−08
Table shows information extracted, summarized, and compared from Braineac, CAGEseq, GTEx, and PheGen
datasets. The rs199347 is reported as a GWAS for PD, and it is a significant eQTL mostly in brain, specifically in
cortical regions. It is clear that GPNMB eQTLs are brain specific followed by the heart and skin (for more details
about other tissues and other SNPs, see Supplementary Table 1). Low numbers of less significant QTLs in other
tissues are reported such as gastrointestinal tissues. No eQTLs were detected in other 21 human tissues that GTEx
tested such as liver and kidney. Other reported SNPs are significant eQTLs in the three datasets, and they are in the
same linkage disequilibrium (LD) with the SNP of interest rs199347. It is worth noting that different datasets
reported same effect of rs199347 on GPNMB expression. MOE is the mode of effect. The (−) and (+) indicating
the mode of the effect of the QTL on the expression either increase (+) or decrease (−) in association with the
major allele. The p value is the unadjusted value of eQTL. False discovery rate (FDR) is the adjusted p value with
FDR threshold 1%. The FDR was calculated within each tissue. Braineac and CAGEseq FDR threshold is 1%.
GTEx and PheGen FDR threshold is 5% (for more details, please see Supplementary Tables 1 and 3)
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not be obtained from Braineac as it is a microarray platform
and the probes specific for this transcript were not included in
the array design. Therefore, the comparison between GTEx
and Braineac could not be performed.
Finally, the SNP rs199347 is an eQTL with NUPL2 tran-
script and shows an increased expression in 24 tissues includ-
ing brain, heart, lung, spleen, and skin (FDR ranging from
4.9 × 10−06 to1.2 × 10−19) in GTEx (Table 3 and
Supplementary Table 2). Similar pattern of increasing
mRNA expression of NUPL2 in relation to rs199347 was also
observed in the FCTX, CRBL, and PUTM in Braineac, but it
did not pass the multiple test FDR correction (Fig. 4c). In the
CAGEseq dataset, rs199347 was a significant eQTL in FCTX
(FDR = 3.6 × 10−05) also for the major allele AA (Table 3 and
Supplementary Table 3). An additional eQTL (rs1474347)
was revealed in lymphoblastoid cells with NUPL2 with FDR
1 × 10−04.
Discussion
Over the past two decades, GWA studies have revolutionized
our understanding of common genetic variation and helped us
to map genomic loci that are associated with increased risk for
common human disease. The majority of these risk variants,
however, are not associated with coding changes in expressed
proteins [23], and a major challenge for the research commu-
nity is to identify and understand the subtle functional conse-
quences of non-coding genetic variation linked to disease risk
in the human genome. These functional modifications can be
via altered expression, splicing, and methylation patterns of
targeted transcripts and proteins that can be localized in spe-
cific tissues, regions or cells, and at specific time points in
development or ageing. GWA data provides, therefore, only
the starting point in terms of understanding the functional
impact on transcripts and proteins in the context of disease
etiology. One approach to achieve greater understanding of
the link between genomic variation and functional conse-
quence is to combine GWAS and multiple eQTL studies to
understand the functional effects of risk loci and provide fur-
ther information about the link between genetic association
and cellular mechanisms [24]. Previous analysis of eQTL re-
sults from the Braineac resource revealed that 17.4% of
GWAS SNPs associated with brain-related traits were func-
tional eQTLs [7]. A number of other studies have used same
approach by overlapping GWAS and whole genome eQTL
results for different human diseases to prioritize targeted
loci/transcripts for further biological experiments [2, 10, 21].
Applying an eQTL analysis approach can shed light on
variation in gene expression associated with PD and help to
develop our understanding of disease etiology. Both Braineac
and GTEx gene expression datasets revealed differential ex-
pression levels between different brain regions (Braineac) and
other human tissues (GTEx) for the named transcripts at the
chromosome 7 PD association locus. The data presented
above demonstrate that the risk SNP rs199347 is an eQTL
with the five transcripts we investigated at this locus
(GPNMB , KLHL7 , KLHL7 -AS1 , NUPL2 , a n d
AC005082.12) at different significant levels in different brain
regions, cortex, and PUTM being the highest, as well as in
other human tissues such as heart and skin. It is important to
note that this genomic locus on Chr7p15.3 (∼169 kb) is in
Fig. 2 Genomic location of the Chr7p15.3 locus representing the five
transcripts and SNP rs199347. The figure represents the genomic location
of the genes in the Chr7p15.3 locus, namely, GPNMB, KLHL7, KLHL7-
AS1, NUPL2, and AC005082.12 along with their different isoforms. The
position of rs199347 (intron 2–3 of GPNMB) is also represented. The
GRCh37 build was used to construct the genomic location in this figure
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Fig. 3 Regional distribution of mRNA expression patterns of the three
transcripts (GPNMB, KLHL7, and NUPL2) in Chr7p15.3 locus in
Braineac. A Box plot of mRNA expression levels for GPNMB in 10
brain regions, from microarray experiments on a log2 scale (y axis).
CRBL cerebellum, OCTX occipital cortex, FCTX frontal cortex, TCTX
temporal cortex, SNIG substantia nigra, WHMT white matter, HIPP
hippocampus, PUTM putamen, THAL thalamus, MEDU medulla. This
plot shows that GPNMB expression in TCTX is higher by 2.4-fold
change (FC) compared with CRBL. B Box plot of mRNA expression
levels for KLHL7 in 10 brain regions, from microarray experiments on a
log2 scale (y axis). This plot shows that KLHL7 expression in CRBL is
higher by 1.5 FC compared with WHMT. C Box plot of mRNA expres-
sion levels for NUPL2 in 10 brain regions, from microarray experiments
on a log2 scale (y axis). This plot shows thatNUPL2 expression in TCTX
is higher by 1.2 FC compared with SNIG.Whiskers extend from the box
to 1.5 times the inter-quartile range.Whiskers extend from the box to 1.5
times the inter-quartile range
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high LD block structure based on the HapMap project [25], a
fact further emphasized by the spread of genome wide signif-
icant SNPs identified in the PD GWAS and displayed in
Fig. 1. It is therefore challenging to dissect and specify from
which gene/transcript the signal is driven, although the in-
crease in the expression of GPNMB in multiple datasets
(Braineac, CAGEseq, and GTEx), and the localization of the
most significant risk SNP at the locus to the GPNMB gene,
suggests that theGPNMB is the most logical candidate coding
gene in the Chr7p15.3 locus. These data, however, do not
exclude potentially important functional roles for the other
transcripts, antisense, and sense non-coding RNA species
within this locus. GPNMB revealed brain-specific eQTLs in
most brain regions, which are reported and confirmed in both
datasets (refer to Table 1). In addition, based on a recent study
that identified PD risk loci that linked to immune system rel-
evant to PD [23], no eQTLs were observed in any immune
system tissues (e.g., spleen and lymphoblastoid cells) in all
three datasets for this transcript. For NUPL2 and KLHL7, only
eQTLs in brain and other human tissues from CAGEseq and
GTEx passed the FDR threshold (refer to Table 3). KLHL7-
AS1 revealed the most significant eQTLs in brain tissues in the
GTEx dataset (refer to Table 4). It is worth noting that the
KLHL7 transcript demonstrates significant eQTL in only 5
out of 44 tissues in GTEx, while KLHL7-AS1 shows signifi-
cant associations with the risk SNP in 43 tissues with an op-
posite effect on the expression. This supports a role for the
antisense RNA as a key regulator of KLHL7 in diverse tissues
and demands more consideration in future studies to under-
stand its interaction with other transcripts in greater detail. In
addition, expression of the long non-coding RNA
AC005082.12 was increased in a range of human tissues (al-
though notably not brain tissue) as an eQTL associated with
rs199347 (refer to Table 4). Interestingly, rs199347 eQTL
shows differences in its effects on the mRNA expression pat-
terns in the brain tissues, as it shows higher expression with
the major allele in case of GPNMB, KLHL7, and NUPL2, but
shows decreasing in the expression of KLHL7-AS1. The data
reported by Nalls et al. indicated that the rs199347 is associ-
ated with increased expression of NUPL2 and decreased
methylation of GPNMB in FCTX and CRBL brain regions
[3]. Previous studies compared single-cell-type specific ex-
pression patterns for human GPNMB in the mouse astrocytes,
neurons, OPC, oligodendrocytes, microglia, and endothelial
tissues, demonstrating that GPNMB is highly expressed in
glial cell populations, while the expression in neurons is min-
imal. This calls for further human single-cell expression stud-
ies (Supplementary Fig. 1) [26], which would aid in building
on the existing knowledge regarding cell-specific functional
mechanisms in PD. This suggests a complex role of the eQTL
that could be transcript, tissue, cell specific, and species and
demands further investigations on possible functional interac-
tion between these coding transcripts and antisense and sense
non-coding RNA species in the brain.
A confounding factor when interpreting and understanding
genome wide association data is that reported associations can
be skewed by population-specific aspects of the results. It is of
note that a GWAS conducted in PD, amyotrophic lateral scle-
rosis (ALS), andmultiple system atrophy (MSA) cohorts from
a Han Chinese population reported that GPNMB has no asso-
ciation of rs156429, which is located in intron 6–7 ofGPNMB
gene, Chr7:23,266,401, with PD; this SNP is in strong LD
with rs199347, suggesting that either the association is popu-
lation specific or indicating the need of meta-analyses in large
cohorts in order to eradicate false negative results [27].
In terms of biological roles, GPNMB is a glycoprotein
transmembrane protein of unknown function. It has been re-
ported to have a potential neuroprotective role in the spinal
cord of an ALS mouse model and showed high protein ex-
pression level in CSF of human ALS patients [28].
Intriguingly, GPNMB mRNA and protein expression have
also been linked to Gaucher’s disease [29] and Niemann
Pick type C [30], two lysosomal storage disorders. The former
has important genetic links with PD, reinforcing a potential
link between this protein and PD. Equally of interest is a role
for GPNMB in the severity of IBD models [31], as other PD
link genes (notably LRRK2) have demonstrated a phenotypic
overlap with IBD [4]. A number of studies have linked in-
creased expression of GPNMB to tumors, and indeed,
GPNMB is being used as a potential binding partner for
targeting drugs to cancerous cells [28, 32]. Gene ontology
suggests that the GPNMB plays a role in many molecular
functions, for example, integrin binding, protein complex
Table 2 Brain regions from GTEx and relevant regions in Braineac
GTEx (brain regions) Braineac
Anterior cingulate cortex (BA24) NA
Amygdala NA
Caudate (basal ganglia) NA
Cerebellar hemisphere Cerebellum (CRBL)
Cerebellum Cerebellum (CRBL)
Cortex Frontal cortex (FCTX)
Occipital cortex (OCTX)
Temporal cortex (TCTX)
Frontal cortex (BA9) Frontal cortex (FCTX)
Hippocampus Hippocampus (HIPP)
Hypothalamus NA
Nucleus accumbens (basal ganglia) NA
Substantia nigra Substantia nigra (SNIG)
Spinal cord (cervical c-1) NA
Putamen (basal ganglia) Putamen (PUTM)
Table shows the different brain regions from GTEx (13 regions) and
Braineac (10 regions) considered for comparison as not all brain regions
in both studies overlap
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Fig. 4 The effect of rs199347 on the expression levels of transcripts
(GPNMB, KLHL7, and NUPL2) in Chr7p15.3 locus in Braineac. A
Box plot shows GPNMB expression stratified by rs199347 in 134 brain
samples. Increased expression was associated with the homozygous
major allele (AA) in TCTX, FCTX, OCTX, HIPP, CRBL, and PUTM.
A similar pattern was observed in other brain regions, but not as signif-
icantly. B Box plot shows KLHL7 expression stratified by rs199347 in
134 brain samples. No significant association was observed after multiple
testing correction FDR was applied. C Box plot shows NUPL2 expres-
sion stratified by rs199347 in 134 brain samples. The SNP is associated
with increased expression in CRBL, TCTX, and FCTX, although no
significant association was observed after multiple testing correction
FDR was applied. Whiskers extend from the box to 1.5 times the inter-
quartile range
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binding, ion binding, and receptor binding. NUPL2 is part of
nuclear export signal receptor, mRNA transport, and estab-
lishment of RNA localization. KLHL7 acts as a mediator for
protein ubiquitination and modification [33, 34]. Further bio-
logical investigation relating to the role of these genes in
cellular pathways and function is vital and could clarify a
putative role for one of these genes in association with the
eQTL in PD.
In summary, the results of this study reinforce a need for
greater functional characterization of the biological roles of
Table 3 rs199347 eQTLs for
KLHL7 and NUPL2 in brain and
other human tissues in GTEx,
CAGEseq, and PheGenI
GTEx
Gene name SNP No. of tissue Tissue specificity MOE FDR
KLHL7 rs199347 93 Brain—nucleus accumbens (basal ganglia) − 1.40E−06
159 Heart—atrial appendage + 2.40E−06
190 Heart—left ventricle + 3.70E−10
361 Muscle—skeletal + 2.50E−07
278 Thyroid − 5.90E−07
Total 1081 5 tissues
NUPL2 rs199347 298 Adipose—subcutaneous − 1.20E−19
185 Adipose—visceral (omentum) − 1.70E−10
126 Adrenal gland − 2.60E−09
197 Artery—aorta − 2.00E−07
285 Artery—tibial + 3.20E−06
89 Brain—cerebellar hemisphere + 8.30E−13
103 Brain—cerebellum + 1.10E−13
96 Brain—cortex + 4.90E−08
93 Brain—nucleus accumbens (basal ganglia) + 3.90E−06
183 Breast—mammary tissue + 1.50E−08
272 Cells—transformed fibroblasts + 2.40E−08
169 Colon—transverse + 3.50E−10
127 Esophagus—gastroesophageal junction + 4.40E−08
218 Esophagus—muscularis + 7.30E−07
159 Heart—atrial appendage + 2.70E−13
190 Heart—left ventricle + 1.20E−17
278 Lung + 1.10E−10
361 Muscle—skeletal + 4.20E−11
256 Nerve—tibial + 4.30E−17
196 Skin—not Sun exposed (suprapubic) + 1.80E−06
302 Skin—Sun exposed (lower leg) + 2.30E−06
89 Spleen − 2.40E−07
278 Thyroid + 7.40E−08
338 Whole blood + 4.90E−06
Total 4888 24 tissues
PheGenI
NUPL2 rs1474347 60 Lymphoblastoid NA 1.08E−04
CAGEseq
NUPL2 rs199347 119 Brain frontal cortex + 3.59E−05
Table shows information extracted and summarized fromGTEx, CAGEseq, and PheGenI datasets for rs199347 in
association with the other transcripts in the GPNMB locus, KLHL7 and NUPL2. The rs199347 is a significant
eQTL with KLHL7 in the basal ganglia in brain and thyroid causing decrease in the expression of the transcript
with the major allele, while it is causing increase in the expression of the same transcript in heart and muscles. For
NUPL2, this SNP is an eQTL in 24 tissues including adipose, heart, brain, muscle, and lung with highest
significance association in CRBL. MOE is the mode of effect. The (−) and (+) indicate the mode of the effect
of the QTL on the expression, either increase (+) or decrease (−) in association with the major allele. GTEx FDR
threshold is 5% and CAGEseq FDR threshold is 1% (for more details, please see Supplementary Tables 2 and 3)
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the genes at this locus in order to determine their potential role
in the etiology of PD, with GPNMB prioritized for such treat-
ment. These data also further emphasize the challenges pre-
sented by the GWA analyses with regard to developing a
detailed mechanistic understanding of pathways to disease
and highlights the importance of combining genetic ap-
proaches with functional analysis and investigations to im-
prove resolution of these issues. The data presented herein
suggests that an increased expression of GPNMB in brain
tissue underlies the association between PD risk and chromo-
some 7p15.3. With currently available datasets and analysis
techniques, however, it is not possible to exclude alterations in
other genes at the locus as the causative link between 7p15.3
and PD. Further experimental investigation into gene expres-
sion and functional variation at this locus is, therefore, a
priority.
Table 4 rs199347 eQTLs for
KLHL7-AS1 and AC005082.12 in
brain and other human tissues in
GTEx
GTEx
Gene name SNP No. of tissue Tissue specificity MOE FDR
KLHL7-AS1 rs199347 72 Brain—anterior cingulate cortex (BA24) − 1.10E−06
100 Brain—caudate (basal ganglia) − 2.90E−08
89 Brain—cerebellar hemisphere − 2.80E−07
103 Brain—cerebellum − 1.10E−08
96 Brain—cortex − 5.40E−13
92 Brain—frontal cortex (BA9) − 5.10E−08
81 Brain—hippocampus − 1.50E−06
81 Brain—hypothalamus − 1.30E−07
93 Brain—nucleus accumbens (basal
ganglia)
− 2.90E−07
82 Brain—putamen (basal ganglia) − 7.10E−08
89 Spleen + 3.00E−10
Total 978 11 tissues
AC005082.12 rs199347 298 Adipose—subcutaneous − 1.10E−14
185 Adipose—visceral (omentum) − 2.00E−12
126 Adrenal gland − 2.30E−07
197 Artery—aorta − 3.00E−07
285 Artery—tibial − 2.30E−08
183 Breast—mammary tissue − 1.70E−09
124 Colon—sigmoid − 1.30E−08
127 Esophagus—gastroesophageal junction − 1.50E−06
241 Esophagus—mucosa − 3.90E−11
218 Esophagus—muscularis − 3.60E−09
159 Heart—atrial appendage − 2.20E−10
190 Heart—left ventricle − 2.40E−11
278 Lung − 1.60E−07
256 Nerve—tibial − 3.70E−06
196 Skin—not Sun exposed (suprapubic) − 3.30E−07
302 Skin—Sun exposed (lower leg) − 5.40E−10
278 Thyroid + 1.10E−08
338 Whole blood − 6.80E−09
Total 3981 18 tissues
Table shows the information extracted and summarized from GTEx datasets for rs199347 in association with the
other transcripts in the GPNMB locus, KLHL7-AS1 and AC005082.12. The rs199347 is a significant eQTL with
KLHL7-AS1 in the brain (cortex, PUTM, and HIPP) and other 33 human tissues with higher significant FDR
values. The SNP has the same effect in all brain regions by decreasing the expression of the transcript with the
major allele. However, there is opposite effect in the spleen. The same effect on the expression of the long non-
coding RNA AC005082.12 is also observed in 18 human tissues but not the brain. MOE is the mode of effect. The
(−) and (+) indicating the mode of the effect of the QTL on the expression either increase (+) or decrease (−) in
associationwith the major allele. GTEx FDR threshold is 5% (for more details, please see Supplementary Table 2)
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Materials and methods
Expression and eQTL analysis
Transcripts within Chr7p15.3 locus (genomic location
Chr7:23,145,089–23,314,256 bp, ∼169 kb, GRCh37) tagged
by the risk SNP rs199347 in PD GWAS study [3] were taken
as potential candidates for expression (eQTL) analysis.
eQTL reporting and analysis were performed on several
datasets including the in-house dataset, Braineac, which
contains Brain tissues originating from 134 control indi-
viduals collected by the Medical Research Council
(MRC) Sudden Death Brain and Tissue Bank, Edinburgh.
The dataset contains brain tissues from the following re-
gions: FCTX Brodmann areas 9 and 46; TCTX Brodmann
areas 21, 41, and 42; parietal parasaggital (PCTX)
Brodmann areas 3, 1, and 2; OCTX (specifically primary
visual cortex) Brodmann area 17; HIPP; thalamus (THAL);
PUTM; SNIG; medulla (MEDU; specifically inferior
olivary nucleus); CRBL; and intralobular WHMT below
Brodmann areas 39 and 40. RNA isolation and processing
of brain samples were performed and analyzed using
Affymetrix Exon 1.0 ST Arrays. In parallel, genomic
DNA was extracted and gentotyped on the Illumina
Infinium Human Omni1-Quad BeadChip. The QTL analy-
sis was run for each expression profile (either exon level or
transcript level) against every genetic marker (either SNP
or indel) in Matrix eQTL [35]. Subsequent analyses were
conducted in R open source software. A detailed descrip-
tion of the samples used in the study, tissue processing,
dissection, and analysis pipeline is provided in main pub-
lished papers for Braineac dataset [4, 7, 17]. ANOVA mod-
ules (method of moments) were performed using Partek®
Genomics Suite™ to determine differentially expressed
transcripts among 10 regions. The date of array hybridiza-
tion (batch effects), gender, region, and individual were
included as covariates to eliminate the possibility of vari-
ability that influences the expression profiles. All p values
were corrected for multiple comparisons using the FDR
step-up method. The eQTL results were classified by the
marker type, SNP or indel; expression type, exon or gene/
transcript level; and the distance of SNP to the transcrip-
tion start site, cis or trans. Then, the FDR was calculated by
Matrix eQTL [35] based on the Benjamin-Hochberg meth-
od. Basically, it takes into account the multiple tests per-
formed based on a single probe, which includes all the
SNPs around 1 Mb window of the boundaries of the probe.
Only the associations with FDR <1% were considered for
the subsequent analyses. All data is now publicly available
online at http://www.braineac.org/. The eQTLs obtained
for the transcripts in the Chr7p15.3 locus in Braineac
dataset were cross verified in multiple datasets from the
GTEx portal and NCBI’s PheGenI in brain and different
tissues. All the QTL data were downloaded, collected, and
summarized in Table 1 and Supplementary Table 1 based
on the most significant SNP as eQTL and tissue specificity.
GTEx dataset [36] consists of a total of 8555 samples
from 53 tissues of 544 donors for which RNAseq was
conducted. The dataset has eQTL analysis for 7051 sam-
ples from 44 tissues of 449 individuals which combine
genotype data from whole exome and genome sequencing
as well as expression data from microarray and RNA se-
quencing. eQTL analysis was performed using Matrix
eQTL [35]. FDR of 5% threshold was used to correct for
multiple hypothesis. Data is available from the publicly
available database at http://www.gtexportal.org/home/.
Data was downloaded on July 2016, version 6. It is
noteworthy that not all the brain regions in Braineac and
GTEx datasets directly overlap. In these cases, the most
relevant and closest region was taken for comparison. See
Table 2 for more details.
PheGenI merges the NHGRI-GWAS catalogue data with
several databases at NCBI, including Gene, dbGaP, OMIM,
GTEx, and dbSNP. The eQTL data consists of 1269 samples
from 7 tissues. The data is available at NCBI’s PheGenI
website (http://www.ncbi.nlm.nih.gov/gap/phegeni) or in
the eQTL browser (https://www.ncbi.nlm.nih.gov/projects/
gap/eqtl/index.cgi). CAGEseq data was obtained from a
previous published study consisting 119 FCTX samples.
eQTL analysis was performed using Matrix eQTL with
covariate postmortem interval, age, gender, and RNA
integrity number and the first six principal components. A
detailed description of the included samples, library
preparation, and analysis pipeline is provided in main
published paper [21].
Expression in single-cell types of human and mouse brain
tissues
The expression pattern for the transcripts was studied for eight
single-cell types, namely, neurons, astrocytes, oligodendro-
cyte precursor cells, newly formed oligodendrocytes,
myelinating oligodendrocytes, microglia, and endothelial
cells from the database-RNA sequence transcriptome and
splicing database of glia, neurons, and vascular cells of the
cerebral cortex [26]. The data is publicly available at http://
web.stanford.edu/group/barres_lab/brainseqMariko/
brainseq2.html.
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